Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

Survey results suggest that some patients with multiple myeloma may forgo treatment that improves progression-free survival (PFS) if it also increases the risk of adverse events and fails to improve ...

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

The executive order outlines some of the steps the Trump administration has already taken to delay or withhold federal funding and terminate existing grants. However, those actions have been ...

The HHS secretary has canceled nearly $500 million in grants and contracts intended to support mRNA vaccine development.

The One Big Beautiful Bill Act will have negative impacts on cancer patients, oncologists, and the health care system at large, experts say.

Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.

The FDA has expanded the approved indication of IV Avtozma to include the treatment of CRS in patients 2 years of age and older.

Resection beyond contrast-enhancing tumor margins is associated with superior outcomes in patients with primary glioblastoma, a study suggests.